We previously described the generation of a novel Ebola virus (EBOV) vaccine based on inactivated rabies virus (RABV) containing EBOV glycoprotein (GP) incorporated in the RABV virion. Our results demonstrated safety, immunogenicity, and protective efficacy in mice and nonhuman primates (NHPs). Protection against viral challenge depended largely on the quality of the humoral immune response against EBOV GP.
We previously described the generation of a novel Ebola virus (EBOV) vaccine based on inactivated rabies virus (RABV) containing EBOV glycoprotein (GP) incorporated in the RABV virion. Our results demonstrated safety, immunogenicity, and protective efficacy in mice and nonhuman primates (NHPs). Protection against viral challenge depended largely on the quality of the humoral immune response against EBOV GP.
Here we present the extension and improvement of this vaccine by increasing the amount of GP incorporation into virions via GP codon-optimization as well as the addition of Sudan virus (SUDV) and Marburg virus (MARV) GP containing virions. Immunogenicity studies in mice indicate similar immune responses for both SUDV GP and MARV GP compared to EBOV GP. Immunizing mice with multiple antigens resulted in immune responses similar to immunization with a single antigen. Moreover, immunization of NHP with the new inactivated RABV EBOV vaccine resulted in high titer neutralizing antibody levels and 100% protection against lethal EBOV challenge when applied with adjuvant.
Our results indicate that an inactivated polyvalent vaccine against RABV filoviruses is achievable. Finally, the novel vaccines are produced on approved VERO cells and a clinical grade RABV/EBOV vaccine for human trials has been produced.
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The Ebolavirus genus of the Filoviridae family comprises 5 viral species: Bundibugyo virus, Ebola virus (EBOV), Reston virus, Sudan virus (SUDV), and Tai Forest virus [1] . Since the identification of EBOV in the 1970s, at least 20 human outbreaks have been reported in Central Africa [2] . The largest known EBOV outbreak is currently occurring in West Africa, with >25 500 infections and a case fatality rate >50% as of 10 April 2015. Fatal EBOV infection is characterized by flulike symptoms and high fever followed by coagulopathy, hemorrhagic manifestations, shock, and multiorgan failure. Although case fatality rates vary between outbreaks and among viruses, EBOV has been associated with up to 90% lethality [3] . In addition, outbreaks of lethal EBOV infection have been reported in endemic nonhuman primates (NHPs), including gorillas and chimpanzees, with fatalities in the thousands [4] [5] [6] [7] [8] .
The Marburgvirus genus includes the species Marburg virus (MARV) and Ravn virus and also causes hemorrhagic fever with high case fatality rates. A MARV outbreak in Angola in 2004-2005 resulted in 374 reported human cases, with an 88% mortality rate.
Several strategies have been used to identify vaccine candidates that confer protection from EBOV or MARV. Immunization with the EBOV or MARV glycoprotein (GP), which mediates viral attachment and entry [9] , has been shown to confer protection from homologous virus in NHPs. Specifically, delivery of GP by DNA vaccination, by viruslike particles, or by expression from recombinant viruses, including adenovirus, vesicular stomatitis virus (VSV), and paramyxoviruses, has been shown to induce humoral and cellular immunity to EBOV, although the exact correlate(s) of protective immunity remain incompletely defined [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Because of unsuccessful cross-protection studies and the known high amino acid sequence divergence of GP across the species of EBOV and MARV, it is believed that a multivalent vaccine will be required to provide protection from all filoviruses [13] . Using recombinant VSV deleted of its own G protein and expressing EBOV GP or SUDV GP instead did protect against challenge with SUDV or EBOV [21] . Cross-protection against Bundibugyo virus was demonstrated by DNA/adenovirus prime boost vaccination with SUDV and EBOV, indicating the potential for heterologous protection [14] .
Taken together, these prior vaccination strategies have firmly established that efficient immunization with EBOV GP or MARV GP confers protection from lethal virus challenge in rodents and NHPs. Because the disease course of EBOV/SUDV and MARV in humans resembles that observed in NHPs, it is anticipated that human vaccination will be an effective means of disease prevention.
We previously evaluated the safety, efficacy, and immunogenicity of a dual vaccine against EBOV and rabies virus (RABV) in mice and rhesus macaques [22] [23] [24] [25] . Our live replicationcompetent vaccine provided 100% protection after EBOV challenge, whereas the replication-deficient and inactivated candidates provided 50% protection. Our results show that protection depends on the quality of the antibodies rather than the quantity [22] . These results supported the further development of this vaccine platform against other filoviruses, as descri bed below. Here we present data indicating that the previously used inactivated vaccine can be greatly improved by codon optimization of EBOV GP. Moreover, we were able to show that immunizing mice with multiple GP antigens results in immune responses equal to those detected for a single antigen immunization. Finally, we demonstrate that the candidate inactivated virus vaccine plus adjuvant elicits high-titer neutralizing antibodies in NHPs, as measured by an EBOV pseudovirion neutralization assay (PsVNA), and also protects against EBOV.
MATERIALS AND METHODS

Complementary DNA Construction of Vaccine Vectors
The genes encoding codon-optimized EBOV GP or SUDV GP were cloned into the BsiWI and NheI restriction sites of the BNSP333 RABV vector [26] . The resulting plasmids were designated BNSP333-coZGP and BNSP333-coSGP, respectively.
The correct sequences of the 2 plasmids were confirmed by sequencing. Recombinant RABV was recovered, as described elsewhere [27] .
Sucrose Purification and Inactivation of the Virus Particles
BNSP333-coZGP and BNSP333-coSGP were grown and concentrated over a 20% sucrose cushion, as described elsewhere [28] . The virus particles were inactivated with 50 µL of a 1:100 dilution of β-propiolactone (BPL) in cold water per 1 mg of particles. The absence of infectious particles was verified by inoculating BSR (a clone from baby hamster kidney cells [BHK]) cells with 10 μg of BPL-inactivated viruses and passaging the supernatant 3 times.
Vaccine Vector Characterization
The inactivated virus particles were denatured, and 1-3 µg of protein was resolved on a 10% sodium dodecyl sulfate (SDS) polyacrylamide gel and then either stained overnight with SYPRO Ruby for total protein analysis or transferred onto a nitrocellulose membrane for Western blotting. RABV-and EBOV-specific antibodies were used to detect RABV M or EBOV GP. The incorporation of EBOV GP was determined by using AlphaView software (ProteinSimple) to quantify SYPRO Ruby-stained SDS polyacrylamide gels and Western blots.
Animal Ethics Statement
This study was carried out in strict adherence to recommendations described in the Guide for the Care and Use of Laboratory Animals, the Office of Animal Welfare, and the US Department of Agriculture. All animal work was approved by the Institutional Animal Care and Use Committee at Thomas Jefferson University or the National Institute of Allergy and Infectious Diseases (NIAID) Division of Clinical Research Animal Care and Use Committee and performed at the NIAID Integrated Research Facility. All procedures were carried out with animals under isoflurane anesthesia administered by trained personnel and under the supervision of veterinary staff. Mice were housed in cages, in groups of 5, under controlled conditions of humidity, temperature, and light (12-hour light/12-hour dark cycles). Food and water were available ad libidum.
Immunizations
Mouse Studies
Groups of 5 C57BL/6J mice each, 6-8 week old, were immunized intramuscularly with 10 µg of BPL-inactivated virus (3 doses at 0, 14, and 28 days). All intramuscular immunizations were performed by administering 10 µL of BPL-inactivated virus into each hind leg muscle. Serum samples were collected retro-orbitally from mice under isoflurane anesthesia on days 0, 7, 14, 21, 28, 35, and 84. Serum samples from individual mice were analyzed for RABV G, EBOV GP, or SUDV GP immunoglobulin (Ig) G, IgG2c, and IgG1 responses, as described elsewhere.
NHP Studies
Six cynomolgus macaques (Macaca fascicularis) were immunized intramuscularly on days 0 and 42, with 100 µg of BPLinactivated BNSP333-coZGP virions supplemented by the respective adjuvant: 20447 and 27837 (Toll-like receptor [TLR] 1/2 agonist) or 20410 and 27914 (TLR3 agonist). Control NHPs (17847 and BB211E) were mock-immunized with phosphate-buffered saline. All animals were challenged at week 10 (4 weeks after the last immunization) with 100 plaque-forming units of EBOV (strain Kikwit).
Analysis of Immune Response to Immunization
Individual mice serum samples were tested for the presence of IgG specific to EBOV GP or SUDV GP by enzyme-linked immunosorbent assay (ELISA), as described elsewhere [25] . In addition, IgG subclass specific ELISAs were performed at a 1:1000 dilution using secondary antibodies specific for mouse IgG1 and IgG2c. ELISA data were analyzed with GraphPad Prism software (GraphPad, version 6.0). The IgG ELISA of serum samples from NHPs were analyzed as described elsewhere [22] .
PsVNA Determination of Virus Neutralizing Antibody (VNA) Against EBOV GP
Serum samples from individual NHPs vaccinated with the RABV-vectored vaccine were evaluated for the presence of neutralizing antibodies with a PsVNA. The PsVNA involves the use of recombinant VSV ΔG with a luciferase reporter (VSV*rLuc). Pseudovirions are produced using plasmids to provide viral GPs that pseudotype VSV*rLuc. EBOV Zaire 95 (Kikwit) and EBOV Zaire 76 (Mayinga) pseudovirions were produced using GPencoding plasmids pWRG7077 EBOVco, [29] and pWRG/ EBOV-Z76(opt), respectively.
The method of pseudovirion production has been described elsewhere [30, 31] . The PsVNA was performed essentially as described elsewhere [32] . Briefly, dilutions of heat-inactivated NHP serum samples were mixed with an equal volume of complete Eagles' Minimum Essential Medium containing EBOV pseudovirion (96-well plate with approximately 4000 focus-forming units per well) and 10% (vol/vol) human complement (Sigma). This mixture was incubated overnight at 4°C and then inoculated (50 µL per well) onto Vero cell monolayers in a clear bottom black-walled 96-well plate. Plates were incubated at 37°C for 18-24 hours, and then the monolayers were lysed. Luciferase reagent was added, and plates were read using a Tecan M200 Pro microplate reader. Raw data (relative light unit values) were exported to GraphPad Prism software (version 6.04) where the percentage neutralization data were normalized to the untreated pseudovirion signal. Percentage neutralization data were fit to a 4-parameter logistic equation using GraphPad Prism software, and PsVNA 50% and 80% neutralization titers were then interpolated from the curves for each sample. Geometric mean titers for replicates are reported.
RESULTS
Effect of Codon Optimization of EBOV GP on Incorporation Into RABV Virions
In our previous studies in NHPs, we found evidence that the quality of the humoral immune response is important for protection from EBOV challenge. Our results indicated that the RABV GP (G) shows a consistent T-helper (Th) 1 bias after immunization in NHPs, whereas the antibodies directed against EBOV GP were generally Th2 biased [22] . Interestingly, the Th2 bias of the anti-GP humoral responses changed to a more Th1-biased phenotype after EBOV challenge in the surviving animals [22] . We hypothesize that the high density of RABV G on the surface of the viral particles might be one factor determining the quality of the immune response evoked; therefore, the increase in the incorporation of EBOV GP into RABV virions might result in a similar Th1 bias for EBOV GP, as seen for RABV G.
For RABV, some foreign viral or cellular proteins are better incorporated into RABV virions if they contain the RABV G cytoplasmic domain [33] . However, our studies for EBOV GP indicated that wild-type EBOV GP is expressed and incorporated just as well as a modified version of EBOV GP containing the RABV G cytoplasmic domain [25] . Therefore, we chose to increase the expression level of EBOV GP, because higher levels of protein on the cell surface should result in higher incorporation levels of EBOV GP into budding RABV, as shown elsewhere for Hendra virus G [28] . Codon optimization has been widely used to increase the expression levels for a variety of cellular and viral proteins; therefore, we codon-optimized the EBOV GP sequence for codon use in human cells. The new DNA sequence was used to replace the wild-type EBOV GP sequence in BNSP333-ZGP, and the new vaccine vector was designated as BNSP333-coZGP and successfully recovered by standard methods (Figure 1 ). To analyze the EBOV GP expression levels of BNSP333-coZGP compared with BNSP333-ZGP, we infected Vero cells with each virus and analyzed them with fluorescence-activated cell sorting for cellular protein production as well as expression levels at the cell surface. Our results indicate that the codon optimization increased expression of EBOV GP within the cell as well as on the surface of the infected cells (data not shown). Next, we determined whether the increase in EBOV GP expression did indeed result in higher amounts of EBOV GP in BNSP333-coZGP virions by analyzing purified virions derived from Vero cells on a 10% SDS polyacrylamide gel. Western blot analysis of sucrose-purified virus particles derived from BNSP333-ZGP and BNSP333-coZGP showed an additional band (EBOV GP2) of about 25 kD for both BNSP333-ZGP and BNSP333-coZGP (Figure 2A) , which was not detected for BNSP333 virions. Quantification of GP of the Western blot indicated an approximate 4-fold increase in incorporation for BNSP333-coZGP compared with BNSP333-ZGP. We also quantified the virions derived from BNSP333-coZGP on SYPRO Ruby-stained gels and found that EBOV GP incorporation was about 10% of the total protein in BNSP333-coZGP virions.
A Novel RABV Vector Expressing SUDV GP
This study was not only directed to improve the RABV-based EBOV vaccine but also to include a vaccine vector directed against SUDV, another filovirus of concern that is antigenically distinct from EBOV. No cross-protection has been shown between these 2 species. Based on the results with the codonoptimized EBOV GP, we also used codon-optimized SUDV GP, which was cloned into BNSP333. Recombinant BNSP333-coSGP (Figure 1 ) was recovered and characterized (data not
Immune Responses to the Vaccines in Mice
The goal of this study was to develop an improved RABV vaccine against filoviruses that induces strong humoral GP-specific immune responses. For this approach, we compared the antibody responses against EBOV GP induced by the 2 vaccine vectors expressing wild-type or codon-optimized EBOV GP. We also performed an analysis to determine whether 2 vectors expressing EBOV GP and SUDV GP can be combined into a single immunization to induce immune responses against both GP antigens. For this approach, 5 groups of 5 mice each were immunized with 10 µg of purified, inactivated virions derived from BNSP333 (empty vector), BNSP333-ZGP, BNSP333-coZGP, BNSP333-coSGP, or BNSP333-coZGP and BNSP333-coSGP on days 0, 7, and 28. The immunization schedule follows the recommendation for preexposure immunization of humans against RABV [34] .
At 14 days after immunization (7 days after the first boost), the 3 groups immunized with virions containing EBOV GP showed a strong IgG response against EBOV GP. There was no significant difference in responses between BNSP333-ZGP and BNSP333-coZGP, indicating that codon optimization did not have an effect on the amount of total IgG, which was similar for the other time points analyzed. The results also show that immunization with 2 antigens does not affect the immune responses generated against EBOV GP or SUDV GP. Interestingly, there was some cross-reactivity for serum samples from SUDV GP-immunized mice to EBOV GP at day 14, 21, 28, and 35, but these responses were short-lived and not detected at the end of the study (day 84). For the SUDV GP-specific ELISA, an immune response could be detected as early as 7 days after immunization, indicating that SUDV GP might be more immunogenic than EBOV GP, at least in mice. As seen for the double-immunized animals with the EBOV GP ELISA (Figure 3) , the SUDV-specific ELISA also indicates that immunization with 2 antigens and immunization with the single antigen BNSP333-coSGP result in similar humoral responses (Figure 4) .
Quality of the Humoral Responses After Immunization in Mice
As indicated above, the quality rather than the amount of the antibodies did affect the outcome of the challenge with EBOV in NHPs [22] . Therefore, we analyzed the induced IgG isotypes against the EBOV or SUDV GP in the immunized mice. As shown in Figure 5A , the IgG1 and IgG2c immune responses against EBOV GP were inconsistent because group 2 (BNSP333-ZGP) had a Th2-biased humoral response at 14 Figure 3 . Murine humoral immune response to Zaire glycoprotein (GP). Serum samples were analyzed for total immunoglobulin G with an Ebola virus (EBOV) GP-specific enzyme-linked immunosorbent assay for days 7 (first boost) (A), 14 (B), 21 (C), 28 (second boost) (D), 35 (E ), and 84 (F). Optical density readings at 490 nm (OD 490 ) were compared with an anti-EBOV GP monoclonal antibody. Serum samples obtained before immunization on day 0 were used as negative controls. All samples were diluted 1:50 and analyzed in a 3-fold serial dilution. days after immunization, whereas groups 3 (codon-optimized ZGP) and 5 (dual antigen, codon-optimized ZGP and codonoptimized SGP) were Th1 biased. This changed after the first boost, when a Th2 bias was detected for most animals of the BNSP333coZGP group. However, and more importantly, the final serum samples from all animals in all groups were of the IgG2c isotype. Interestingly, the Th1 bias was much more pronounced after immunization with SUDV GP-containing virions; all groups presented as Th1 biased for SUDV GP beginning on day 7 and continuing throughout the entire study (Figure 5B and data not shown) .
Finally, we also included the MARV GP construct in our mouse studies. As with the other 2 vaccine vectors, a codonoptimized MARV GP was synthesized and cloned into BNSP333, using standard methods [25] . Our preliminary studies with immunizations of a mixture of inactivated virions from BNSP333- 
Further Development of the RABV-Based Vaccine for Human Use
The improved vaccine (BNSP333-coZGP) was recently tested in 4 NHPs at a dose of 100 µg each with 2 adjuvants, a TLR1/2 agonist (adjuvant 1) and a TLR3 agonist (adjuvant 2). In this setting, the vaccines administered as 2 doses at 6-week intervals protected all animals from challenge with 100 plaque-forming units of EBOV by the intramuscular route. Evaluation of EBOV-GP-specific antibodies showed GP-specific seroconversion, augmented by a boost at week 42 ( Figure 6A) . Moreover, the neutralizing antibody response by PsVNA demonstrated that high-titer neutralizing antibodies were elicited after vaccinations ( Figure 6B ). The week 8 titers in 4 NHPs vaccinated with the BNSP333-coZGP were very high. In all animals the PsVNA 80% and 50% neutralization titers were >1000 and >10 000, respectively. In contrast, the NHPs vaccinated with phosphate-buffered saline had unquantifiable levels of neutralizing antibodies.
The neutralizing antibody responses were similar when EBOV Z76 or EBOV Z95 pseudovirions were used. The observed difference (<2-fold) suggested that the anti-EBOV Z95 response was stronger. There were indications that the TLR3 adjuvant might be slightly more effective at boosting the antibody response, but the small number of animals studied makes it impossible to conclude that there was a difference between adjuvants. Because the final vaccine constructs BNSP333-coZGP, BNSP333-coSGP, and BNSP333-coMARVGP have now been identified, we have recovered and produced these 3 vaccine vectors on approved Vero cells from the Vero Master Cell Bank and are currently in the process of producing the master virus seed for all 3 vaccines. , or phosphate-buffered saline (PBS) (NHP ID 17847 and BB212E). Animals vaccinated with the inactivated rabies virus vaccine BNSP333-coZGP were vaccinated on days 0 and 42, and animals vaccinated with PBS on days 0, 21, and 42. Serum samples collected on days 42 and 54 were evaluated using an Ebola virus (EBOV)-specific enzyme-linked immunosorbent assay (A), and serum samples from day 54 were also analyzed for the presence of VNA by pseudovirion neutralization assay (PsVNA), using both EBOV Z76 and EBOV Z95 pseudovirions. B, PsVNA 50% and 80% neutralization titers (PsVNA 50 and PsVNA 80 ) titers were determined. Geometric mean titers for replicate values are shown with 95% confidence intervals. The positive control was serum samples from rabbits vaccinated 3 times with a EBOV Z76 DNA vaccine plasmid, pWRG/EBOV-Z76(opt), delivered by a PharmaJet disposable syringe jet injection device. The limit of quantification for titers was 20 (dashed line). Dotted lines at 1000 and 10 000 are included for reference points. C, Animals were challenged on day 70 with 100 plaque-forming units of EBOV and viral loads were followed. Abbreviations: BLD, below limit of detection (<10 genome equivalents); HRP, horseradish peroxidase; ND, not determined; OD 490 , optical density at 490 nm; VNA, virus neutralizing antibody .
DISCUSSION
The EBOV outbreak that began in the first quarter of 2014 in West Africa highlighted the need for an efficient EBOV vaccine. Several EBOV vaccines have been developed for human vaccination during the last 5-15 years, using live replicationcompetent vectors, such as paramyxoviruses and VSV; replication-deficient vectors, including adenoviruses, modified vaccinia Ankara virus, or Venezuela equine encephalitis virus; and "killed" vaccines, such as DNA vaccines, viruslike particles, and RABV virions (for review, see [35] ). However, only recently have resources become available to move some of these approaches into human trials. Ideally, these promising vaccine candidates will be proved safe, effective, and affordable so that they can be further developed for mass vaccination.
Whereas these new vaccines will be valuable against EBOV, similar outbreak(s) of hemorrhagic diseases caused by SUDV or MARV cannot be excluded and are not less likely to occur, because these viruses have already played a major role in previous filovirus outbreaks. Therefore, the focus on a monovalent vaccine against EBOV is timely, but the long-term goal should be a multivalent vaccine against filoviruses.
Here we present a study in mice analyzing the improved version of our previous vaccine construct BNSP333-ZGP. Whereas BNSP333-ZGP was efficient as a live viral vector and protected 100% of the NHPs from challenge with pathogenic EBOV, the inactivated virions protected only 50% of the animals. We hypothesized that our current vaccine based on the RABV virions as a carrier for EBOV GP could be improved by increasing the amount of EBOV GP in the virion to levels similar to those of RABV G. We used codon optimization for codon usage in primate cells, which increased expression of EBOV GP, resulting subsequently in a 4-fold increase of EBOV GP in RABV virions. Similar findings have been made for Hendra G, which also increases substantially when the codon usage was adjusted to those for human cells [28] . These results also indicate that foreign GPs are incorporated based on the availability on the cell surface rather than by using specific signals within the cytoplasmic domain. This finding is similar to those previously made for the incorporation of other proteins into RABV virions [36] and supports conclusions concerning VSV, for which certain proteins like human immunodeficiency virus type 1 gp160 contain signal sequences excluding them from rhabdoviral budding sites instead of G protein cytoplasmic signals promoting incorporation [37] .
The results of our mouse studies did indicate that immunization with the codon-optimized GP containing vector BNSP333-coZGP did not result in improved humoral immune responses, compared with the previous vector BNSP333-ZGP. However, our previous studies in mice showed full protection against challenge with a mouse-adapted EBOV after immunization with the inactivated BNSP333-ZGP virions. Of note, our current results indicate that immunization with both vaccines does induce primarily Th1-biased immune responses in mice, which seem beneficial for protection. BNSP333-ZGP did not induce a bias toward Th1 humoral response in NHPs. However, our recent study in NHPs resulted in 100% protection after 2 immunizations with the new inactivated virions. However, the use of a TLR1/2 or TLR3 adjuvant has required additional studies without an adjuvant to determine whether the higher amount of GP is indeed responsible for the protection. Such experiments are currently in progress.
In addition to identifying the Th1 bias after immunization with BNSP333-coZGP, we also performed immunization with inactivated virions. The results indicated that the SUDV GP seems to be more immunogenic, which might explain why SUDV is less lethal than EBOV. Moreover, the SUDV GP immune response was more pronounced toward Th1, which could be attributed to the reduced pathogenicity of SUDV compared with EBOV. Another finding of these studies was that immunization with a mixture of the 2 vaccines induced similar humoral responses as when a single antigen was used. Preliminary data for immunization using the GPs of 3 filoviruses confirmed that MARV GP could also be added without compromising the humoral response for any of the 3 antigens. These results corroborate previous reports of the ability of RABV virions containing different antigens to induce potent immune responses [24, 28, 36, [38] [39] [40] . Finally, we were able to show that, for inactivated virions, preexisting immunity against RABV does not prevent immunization with recombinant virions carrying a novel antigen such as EBOV GP, which is a problem when using live-viral vectors that need to infect and replicate.
The initial study of the second-generation RABV-EBOV vaccine in NHPs had some interesting findings. As shown for other vaccines, there is evidence from our study that EBOV-GPspecific antibodies are an excellent marker for protection against challenge with pathogenic EBOV. Interestingly, ELISA and VNA titers did align well (ie, high ELISA titers resulted in high neutralizing titers), indicating that serum samples might be easily screened with ELISA as a measurement of potential protection. Although different antibody titers were detected for the vaccines with adjuvant 1 and adjuvant 2, both vaccine protocols protected the NHPs, and no virus was detected in their serum samples (Figure 6C) ; therefore, it is likely that protection can be expected within a certain range of antibodies. One concern with the current study could be that the EBOV challenge dose was lower than in other studies, which used up to 10-fold more virus. However, the control animals in this study did succumb to infection within the expected time frame. Further experiments are in progress to determine whether the improvement in protection in the current study compared with the previous study [22] was caused by the newly improved vaccine, the adjuvants, or a combination of both. Moreover, higher challenge doses of the current EBOV outbreak strain will be used.
In summary, the results presented here indicate that protection against filoviruses with a RABV-based EBOV vaccine is feasible. Whereas the disadvantage of the inactivated vaccine might be the need for 2 vaccinations, as for the chimp adenovirus vaccine, the advantage is its excellent safety profile. Adverse effects are still a concern for the currently further developed live viral EBOV vaccine, and current clinical studies do indicate that the vaccines might be less immunogenic in humans than in NHPs [41] [42] [43] . The RABV-based vaccine might still be the safest vaccine for mass vaccination of the general population. Potential conflicts of interest. P. J., J. E. B., R. F. J., and M. J. S. have a pending US patent application entitled "Multivalent Vaccines for Rabies Virus and Filovirus." All other authors report no potential conflicts.
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